Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

H. Hara, H. Kawashima, M. Ono, K. Takahashi, M. J. Mack, D. R. Holmes, M. C. Morice, P. M. Davierwala, F. W. Mohr, D. J. F. M. Thuijs, A. P. Kappetein, N. O'Leary, D. van Klaveren, Y. Onuma, P. W. Serruys

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)


Background: Creatinine clearance (CrCl) is an independent determinant of mortality in predictive models of revascularisation outcomes for complex coronary artery disease. Aims: This study aimed to investigate the impact of preprocedural biological markers on 10-year mortality following coronary revascularisation. Methods: The SYNTAX Extended Survival (SYNTAXES) study evaluated the 10-year vital status followup of 1,800 patients with de novo three-vessel (3VD) and/or left main coronary artery disease (LMCAD) randomised to include percutaneous or surgical coronary revascularisation. The associations between mortality and preprocedural C-reactive protein (CRP), haemoglobin, HbA1c, CrCl, fasting triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were analysed. Results: Out of 1,800 patients, 460 patients died before the 10-year follow-up. CRP, HbA1c and CrCl with threshold values of ≥2 mg/L, ≥6% (42 mmol/mol) and
Original languageEnglish
Pages (from-to)1477-1487
Number of pages11
Issue number18
Publication statusPublished - Apr 2022

Bibliographical note

Funding Information:
The SYNTAX Extended Survival study, which extended the follow-up up to 10 years, was supported by the German Foundation of Heart Research (Frankfurt am Main, Germany). The SYNTAX trial, covering the 0-5 year follow-up, was funded by Boston Scientific (Marlborough, MA, USA).

Funding Information:
H. Hara reports a grant for studying overseas from the Japanese Circulation Society and a grant from the Fukada Foundation for Medical Technology. M.C. Morice is CEO and shareholder of CERC, a CRO not involved in this trial, and is a minor shareholder of ELECTRODUCER. A. Kappetein reports working as an employee of Medtronic, outside the submitted work. P.W. Serruys reports personal fees from Biosensors, Micel Technologies, Sinomedical Sciences Technology, Philips/Volcano, Xeltis, HeartFlow, and SMT outside the submitted work. The other authors have no conflicts of interest to declare.

Publisher Copyright:
© Europa Digital & Publishing 2022. All rights reserved.


Dive into the research topics of 'Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial'. Together they form a unique fingerprint.

Cite this